Human immunodeficiency virus (HIV) — pre-exposure prophylaxis (PrEP)
- Match PrEP to exposure + patient preference
- Daily oral TDF/FTC remains a major option
- TAF/FTC for approved populations
- Long-acting cabotegravir avoids daily pills
- Lenacapavir adds twice-yearly PrEP
- Confirm HIV-negative status before dosing
- Renal/HBV issues affect oral-drug choice
Use at a glance
- Match PrEP to exposure + patient preference
Practical pearls
- Confirm HIV-negative status before dosing
Other practical pearls
- Daily oral TDF/FTC remains a major option
- TAF/FTC for approved populations
- Lenacapavir adds twice-yearly PrEP
Treatment options
- Renal/HBV issues affect oral-drug choice
Safety / pitfalls
- Long-acting cabotegravir avoids daily pills
Self-check
- What should guide PrEP selection?
Exposure pattern and patient preference.
- What must be confirmed before PrEP dosing?
HIV-negative status.
Drugs used for this (4)
All clinical uses · Open the interactive console ↗
